Loading
Starna Therapeutics develops RNA medicines carried in fat particles designed to reach tissues outside the liver. Its STR-P004 aims to turn a patient's own immune cells into CAR-T cells inside the body, and is in an early study in B-cell non-Hodgkin lymphoma.
Starna Therapeutics (Suzhou) Co., Ltd. develops RNA-based medicines on a lipid nanoparticle platform for extrahepatic delivery, with tissue-specific and cell-selective nanoparticles. STR-P004 is an intravenously given in vivo CAR-T drug; the company describes it for autoimmune disease, and the early clinical study NCT07003178 at a single centre in Suzhou tests it in relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma. Its other disclosed programme is STR-V003, a respiratory syncytial virus vaccine. The company reported a Series B of more than 300 million yuan in October 2025, co-led by LYFE Capital, Hillhouse and Lilly Asia Ventures, and a Series B+ of nearly 40 million US dollars in May 2026. Its first registered cancer trial, NCT07003178, was posted on ClinicalTrials.gov in June 2025; its first registry study overall, posted in April 2024, was an RSV vaccine trial.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Series B+ · Nearly 40 million US dollars (近4000万美元) per the company headline, with Hillhouse, LYFE Capital, Lilly Asia Ventures and Chunhwa Ventures among investors; amountUsd omitted because the figure is approximate. | 2026 | undisclosed | starnatx.com |
| Series B · More than 300 million yuan, co-led by LYFE Capital, Hillhouse and Lilly Asia Ventures, as summarised on the company website. No US dollar figure stated. | 2025 | undisclosed | starnatx.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Shares In vivo CAR-T, CD19.
Shares In vivo CAR-T, CD19.
Shares CD19, Non-Hodgkin lymphoma (all types).
Shares In vivo CAR-T, CD19.
Shares In vivo CAR-T, CD19.
Shares CD19, Non-Hodgkin lymphoma (all types).
Shares CD19, Non-Hodgkin lymphoma (all types).
Shares In vivo CAR-T, CD19.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/